Perrigo Company Plc's ability to collect accounts receivable sequentially worsen to 8.52, indicating more challenging environment then in the fourth quarter 2025, but still, it is a far cry from any concerns. Perrigo Plc's Accounts Receivable average collection period in the Mar 28 2026 quarter, has increased to 43 days, from 42 days, in the Dec 31 2025 quarter.

If we take a look into Healthcare sector 308 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Mar 28 2026 from 1587 to 2151.

What is Receivable Turnover Ratio?
What is Perrigo Company Plc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

PRGO Receivables Turnover Ratio	(Mar 28 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 27 2025) III. Quarter	(Jun 28 2025) II. Quarter	(Mar 29 2025) I. Quarter
Y / Y Receivable Change	-2.75 %	-4.59 %	-18 %	-99.1 %	-8.1 %
Y / Y Revenue Change	-7.17 %	-2.52 %	-4.07 %	-0.79 %	-3.55 %
Receivable Turnover Ratio (TTM)	8.52	8.59	8.52	8.04	6.04
PRGO's Total Ranking	# 2151	# 1587	# 1500	# 2186	#
Accounts Receivable average collection period days	43	42	43	45	60
Seq. Receivable Change	13.76 %	-4.9 %	9813.85 %	-99.09 %	11.6 %
Seq. Revenue Change	-12.72 %	6.38 %	-1.25 %	1.25 %	-8.35 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 83
Healthcare Sector	# 309
Overall Market	# 2151

Receivable Turnover Ratio Statistics
High	Average	Low
0.46	0.39	0.27
(Mar 28 2026)		(Sep 26 2015)

News about Perrigo Company Plc Receivables Turnover Ratios

Navigating Legal and Financial Quagmires The Case of Perrigo Company Plc Amidst Competitive Pressures

The pharmaceutical industry is characterized by rapid fluctuations in revenue and intense competition, often pitting companies against one another in the race for market dominance. The recent performance of Perrigo Company Plc (NYSE: PRGO) provides a case study in the complexities of maintaining profitability amid industry challenges. This article examines the company s declining revenues contrasted against its competitors, the legal ramifications from shareholder lawsuits, and the implications of its recent financial performance for stakeholders.Perrigo Company Plc, a notable player in the global healthcare sector, is currently facing scrutiny not only from its financial performance but also from class action lawsuits initiated by its shareholders. Most recently, The Gross Law Firm has issued notices to investors about a class action lawsuit against Perrigo, highlighting the mounting concern over the company’s fiscal health and corporate governance practices.

PRGO Company Profile • Back to PRGO Efficiency Comparisons • Compare PRGO Receivables Turnover Ratio to its Competitors

Financial Statements
Perrigo Plc's Accounts Receivable	$ 697 Millions	Visit PRGO's Balance sheet
Perrigo Plc's Sales TTM	$ 4,178 Millions	Visit PRGO's Income Statement
Sources of PRGO's Revenues		Visit PRGO's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
PRGO's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
PRGO's Growth Rates	PRGO's Roa	PRGO's Inventory Turnover Ratio	PRGO's Dividend Comparisons
PRGO's Profitability Ratios	PRGO's Roi	PRGO's Asset Turnover Ratio	PRGO's Dividend Growth
PRGO's Valuation Ratios	PRGO's Roe	PRGO's Financial Strength Ratios	PRGO's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Mar 28 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Mar 28 2026	Receivable at quarter ending Mar 28 2026
Premier Air Charter Holdings Inc	16.33	$ 33.205 Millions	$ 2.033 Millions
Bioage Labs Inc	15.90	$ 10.316 Millions	$ 0.649 Millions
Escalon Medical Corp	15.15	$ 11.445 Millions	$ 0.756 Millions
Nurix Therapeutics Inc	15.11	$ 71.779 Millions	$ 4.750 Millions
Rosecliff Acquisition Corp I	15.05	$ 23.433 Millions	$ 1.557 Millions
Lexicon Pharmaceuticals Inc	14.91	$ 69.643 Millions	$ 4.670 Millions
Qhslab Inc	14.80	$ 2.775 Millions	$ 0.188 Millions
Nexgel Inc	14.19	$ 10.382 Millions	$ 0.732 Millions
Sutro Biopharma Inc	14.04	$ 99.608 Millions	$ 7.095 Millions
Precipio inc	13.93	$ 25.831 Millions	$ 1.854 Millions
China Pharma Holdings Inc	13.86	$ 3.992 Millions	$ 0.288 Millions
Talkspace Inc	13.67	$ 239.269 Millions	$ 17.501 Millions
Marpai Inc	13.59	$ 17.125 Millions	$ 1.261 Millions
Amneal Pharmaceuticals Inc	13.56	$ 3,045.530 Millions	$ 224.634 Millions
Corcept Therapeutics Inc	13.20	$ 769.096 Millions	$ 58.264 Millions
Xoma Royalty Corporation	13.05	$ 48.555 Millions	$ 3.720 Millions
Mannkind Corporation	13.00	$ 360.783 Millions	$ 27.757 Millions
Lifestance Health Group Inc	12.74	$ 1,494.791 Millions	$ 117.296 Millions
Chemed Corporation	12.73	$ 2,540.548 Millions	$ 199.626 Millions
Milestone Scientific Inc	12.69	$ 8.337 Millions	$ 0.657 Millions
Lftd Partners Inc	12.55	$ 36.955 Millions	$ 2.945 Millions
Clene Inc	12.47	$ 0.134 Millions	$ 0.011 Millions
Skinhealth Systems Inc	12.27	$ 295.223 Millions	$ 24.052 Millions
Cytokinetics Incorporated	12.16	$ 105.815 Millions	$ 8.702 Millions
Precision Biosciences Inc	11.94	$ 45.073 Millions	$ 3.776 Millions
Teladoc Health Inc	11.94	$ 2,514.453 Millions	$ 210.660 Millions
Option Care Health Inc	11.65	$ 5,666.577 Millions	$ 486.439 Millions
Ensysce Biosciences Inc	11.55	$ 4.708 Millions	$ 0.407 Millions
Crinetics Pharmaceuticals Inc	11.52	$ 18.069 Millions	$ 1.569 Millions
Icu Medical Inc	11.46	$ 2,156.379 Millions	$ 188.157 Millions

Date modified: 2026-08-30T14:38:39+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.